Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization-Reference-Cited by-同舟云学术

Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization

Published:2023-09-22 Issue:19 Volume:66 Page:13400-13415
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Nilsson Magnus¹^ORCID,Berggren Kristina¹,Berglund Susanne¹,Cerboni Silvia²,Collins Mia²^ORCID,Dahl Göran³,Elmqvist David⁴,Grimster Neil P.⁵^ORCID,Hendrickx Ramon⁶,Johansson Johan R.¹^ORCID,Kettle Jason G.⁵^ORCID,Lepistö Matti¹,Rhedin Magdalena²,Smailagic Amir²,Su Qibin⁵,Wennberg Tiiu²,Wu Allan⁷,Österlund Torben⁸,Naessens Thomas²,Mitra Suman²

Affiliation:

1. Medicinal Chemistry, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

2. Bioscience, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

3. Structure and Biophysics, Research and Early Development, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

4. Early Product Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

5. Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States

6. DMPK, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

7. Discovery Sciences, R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States

8. Mechanistic Biology & Profiling, Research and Early Development, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00554

Reference78 articles.

1. Mechanisms of Jak/STAT Signaling in Immunity and Disease

2. The molecular details of cytokine signaling via the JAK/STAT pathway

3. Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

4. Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

5. The JAK-STAT pathway at 30: Much learned, much more to do